Skip to content

Granisetron

Serotonin-3 Receptor Antagonist — ALIMENTARY TRACT AND METABOLISM

Also known as: BRL-43694, granisetron HCl, granisetron hydrochloride, granisetron monohydrochloride, kevatril, kytril, sancuso

OfpEMA approvedFDA approvedPMDA approvedATC A04AA02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Granisetron is an ofp drug in the Serotonin-3 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1993. Its mechanism of action is classified as Serotonin 3 Receptor Antagonists. DrugCentral lists 9 molecular targets, including Htr3a|Htr3b, HTR3B and HTR3A. Recorded indications include Chemotherapy-induced nausea and vomiting, Post-Operative Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting and Prevention of Radiation-Induced Nausea and Vomiting.

  • Approval status: ofp (first approved 1993 by the FDA).
  • Drug class: Serotonin-3 Receptor Antagonist.
  • Mechanism of action: Serotonin 3 Receptor Antagonists.
  • Molecular targets: Htr3a|Htr3b, HTR3B, HTR3A and HTR3A (9 listed in DrugCentral).
  • Indications: Chemotherapy-induced nausea and vomiting, Post-Operative Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting and Prevention of Radiation-Induced Nausea and Vomiting.
  • ATC code: A04AA02 (Serotonin (5HT3) antagonists).
  • Molecular formula: C18H24N4O; molecular weight 312.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

  • Chemotherapy-induced nausea and vomiting
  • Post-Operative Nausea and Vomiting
  • Prevention of Post-Operative Nausea and Vomiting
  • Prevention of Radiation-Induced Nausea and Vomiting

Off-label uses (1)

  • Prolonged-Severe Nausea and Vomiting

Contraindications (6)

  • Conduction disorder of the heart
  • Congenital long QT syndrome
  • Doxorubicin Induced Cardiomyopathy
  • Hypokalemia
  • Hypomagnesemia
  • Prolonged QT interval

Mechanism & targets

Mechanism of action (MoA)Serotonin 3 Receptor Antagonists
Established pharmacologic classSerotonin-3 Receptor Antagonist

Molecular targets (9)

TargetGeneActionActivity
Serotonin 3 (5-HT3) receptorHtr3a|Htr3bunknownKi 9.46
5-hydroxytryptamine receptor 3BHTR3BunknownKi 8.80
5-hydroxytryptamine receptor 3AHTR3AantagonistKi 8.70
5-hydroxytryptamine receptor 3AHTR3AunknownKi 8.40
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 5.43
Solute carrier family 22 member 2SLC22A2unknownIC50 5.37
Multidrug and toxin extrusion protein 1SLC47A1unknownIC50 5.30
Neuronal acetylcholine receptor; alpha4/beta2CHRNB2|CHRNA4unknownKi 4.42
Neuronal acetylcholine receptor subunit alpha-3CHRNA3unknownKi 4.17

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2022-02-25PMDA—Taiyo Pharma Co Ltd
2012-04-20EMA—Kyowa Kirin Holdings B.V.
1993-12-29FDA—ROCHE

ATC classification

ATC codeTherapeutic hierarchy
A04AA02ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Serotonin (5HT3) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Febrile neutropenia1174.1
Product adhesion issue697.4
Nausea444.3
Neutropenia335.3
Neutrophil count decreased321.0
Death271.3
Drug ineffective267.7
Anaemia248.9
Pyrexia244.5
Platelet count decreased225.2
Vomiting219.0
Leukopenia211.3

Chemical structure

Molecular formulaC18H24N4O
Molecular weight312.42 g/mol
CAS number109889-09-0
InChIKeyMFWNKCLOYSRHCJ-BTTYYORXSA-N
PubChem CID5284566
CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Granisetron used for?

DrugCentral lists the following indications for Granisetron: Chemotherapy-induced nausea and vomiting, Post-Operative Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting and Prevention of Radiation-Induced Nausea and Vomiting.

How does Granisetron work?

Granisetron is classified as Serotonin 3 Receptor Antagonists; its molecular targets in DrugCentral include Htr3a|Htr3b, HTR3B, HTR3A (antagonist) and HTR3A.

When was Granisetron first approved?

Granisetron was first approved by the FDA in 1993.

What drug class does Granisetron belong to?

Granisetron is in the Serotonin-3 Receptor Antagonist class.

What is the chemical formula of Granisetron?

Granisetron has the molecular formula C18H24N4O and a molecular weight of 312.42 g/mol.

Browse: all drugs starting with G · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1993-12-29
AgencyFDA
Targets9
Indications4
FormulaC18H24N4O
DrugCentral ID1329
Interactive profile